Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan in Diastolic Heart Failure
NCT00303498Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2006
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Sitaxsentan sodium with Placebo (2 arms). Primary endpoint: Change From Baseline in Treadmill Exercise Time at 24 weeks. Started Mar 2006; status: completed.
02
Drugs
sitaxsentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00303498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303498.